Vanguard Group Inc. Boosts Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Vanguard Group Inc. grew its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 52,537,446 shares of the company’s stock after buying an additional 2,155,429 shares during the period. Vanguard Group Inc. owned 11.50% of GE HealthCare Technologies worth $4,107,378,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Runnymede Capital Advisors Inc. purchased a new stake in GE HealthCare Technologies during the fourth quarter valued at about $28,000. Continuum Advisory LLC lifted its stake in shares of GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares in the last quarter. Bank of Jackson Hole Trust acquired a new position in shares of GE HealthCare Technologies in the 4th quarter valued at about $32,000. OFI Invest Asset Management purchased a new stake in shares of GE HealthCare Technologies during the 4th quarter worth about $34,000. Finally, Flagship Wealth Advisors LLC acquired a new stake in GE HealthCare Technologies during the 4th quarter worth approximately $34,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

GE HealthCare Technologies Price Performance

GEHC stock opened at $81.70 on Tuesday. The company has a market capitalization of $37.36 billion, a PE ratio of 18.87, a P/E/G ratio of 3.19 and a beta of 1.13. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The stock’s 50 day moving average is $86.94 and its two-hundred day moving average is $85.98. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The business had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Analysts predict that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on GEHC. Wells Fargo & Company boosted their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their price target for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. The Goldman Sachs Group raised GE HealthCare Technologies from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $100.00 in a research report on Tuesday, March 11th. Finally, Citigroup upped their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $98.75.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.